Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

1001. Herbal medicines for asthma: a systematic review

), and Tylophora indica (T. indica); traditional Japanese (Kampo) herbal medicine, i.e. Tsumura saiboku-to (TJ-96); marihuana (smoking and in capsule form) and dried ivy leaf extract. Participants included in the review Asthma. To be included in the review, trials preferably defined asthmatic participants by ATS criteria; if this was not possible they were defined as those who had reversible airway constriction. Studies involving experimentally-induced asthma or people suffering from other medical conditions (...) in addition to their asthma were excluded. Most of the studies included in the review involved 'bronchial' asthmatics. Some included steroid-dependent asthmatics, cold-type, heat-type, seasonal or severe asthmatics. Outcomes assessed in the review The outcome measures considered were lung function parameters, symptom diaries, medication usage and asthma events. The latter comprised unscheduled visits to doctors, antibiotics, prednisolone, or days missed from school or work. Immunological studies were

2000 DARE.

1002. Breathing techniques. Adjunctive treatment modalities for asthma: a systematic review

Breathing techniques. Adjunctive treatment modalities for asthma: a systematic review Breathing techniques. Adjunctive treatment modalities for asthma: a systematic review Breathing techniques. Adjunctive treatment modalities for asthma: a systematic review Ernst E Authors' objectives To determine whether or not breathing techniques are effective in the relief of asthma symptoms. Searching The author searched MEDLINE, EMBASE, CISCOM, and the Cochrane Library to December 1996 using the following (...) search terms: 'asthma', 'breathing techniques/exercise', 'yoga', 'Buteyko' and 'physiotherapy'. Additional material was obtained by contacting experts in the field, scanning personal files, and examining bibliographies of retrieved studies. There were no restrictions on language of publication. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review Breathing techniques including slow deep

2000 DARE.

1003. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies

Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2000 DARE.

1004. Efficacy of magnesium sulfate in acute adult asthma: a meta-analysis of randomized trials

=0.30, P=0.6). Side-effects: in one trial minor side-effects such as flushing, mild fatigue, and burning at the intravenous site, were noted in 58% of patients who received MgSO4. Authors' conclusions The authors state that the existing evidence reveals that the administration of MgSO4 to ED patients with moderate to severe asthmatic exacerbations does not alter treatment outcomes. The authors conclude that MgSO4 does not have a role in the initial treatment of acute asthma patients. Nevertheless (...) that with further evidence, such as another RCT, the use of MgSO4 could play a role in the treatment of near intubation asthmatics (forced expiratory volume in 1 s less than 25%); this has been suggested in a number of case reports. Bibliographic details Rodrigo G, Rodrigo C, Burschtin O. Efficacy of magnesium sulfate in acute adult asthma: a meta-analysis of randomized trials. American Journal of Emergency Medicine 2000; 18(2): 216-221 PubMedID Other publications of related interest 1. Glass GV. Meta-analysis

2000 DARE.

1005. Long-acting beta2-agonists in management of childhood asthma: a critical review of the literature

Long-acting beta2-agonists in management of childhood asthma: a critical review of the literature Long-acting beta2-agonists in management of childhood asthma: a critical review of the literature Long-acting beta2-agonists in management of childhood asthma: a critical review of the literature Bisgaard H Authors' objectives To evaluate the use of long-acting beta2-agonists in the management of paediatric asthma. Searching Full articles were sought by searching MEDLINE, EMBASE, Current Contents (...) and a nonsystematic review of asthma literature up to 1999. Abstracts were excluded. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) and double-blind studies that reported clinical outcomes were included. Specific interventions included in the review Inhaled formoterol and salmeterol, either alone or in combination with inhaled steroids, were compared with placebo, salbutamol, beclomethasone diproprionate (BDP), unspecified inhaled steroids, cromoglycate

2000 DARE.

1006. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis

The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis Sharek P J, Bergman D A Authors' objectives To determine whether inhaled steroid therapy causes delayed linear growth in children with asthma. Searching MEDLINE from 1966 to 1998, EMBASE from 1980 to 1998 and CINAHL from (...) steroids (beclomethasone, budesonide, flunisolide, fluticasone, triamcinolone) delivered by any device (diskhaler device, metered-dose inhaler), compared to non-steroidal medication or placebo. Non-steroidal medications reported in the review included salmeterol and theophylline. Participants included in the review Children (<18yrs old) with a clinical diagnosis of asthma who were not using oral steroids. Studies reported in the review included children from 6 to 16yrs old, with four out of five trials

2000 DARE.

1007. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) Shrewsbury S, Pyke S, Britton M Authors' objectives To examine the benefits of adding salmeterol compared with increasing dose of inhaled corticosteroids in symptomatic asthma (...) in the review Salmeterol (dose not stated) with inhaled corticosteroids 200 to 1000 micrograms/day (baseline) compared with an increasing dose (at least double, 400 to 2000 micrograms/day) of inhaled corticosteroids (beclometasone dipropionate or fluticasone). Participants included in the review Patients twelve years and older with symptomatic asthma in primary or secondary care settings. Outcomes assessed in the review Efficacy (defined as mean difference in lung function) and exacerbation of asthma

2000 DARE.

1008. Improved outcomes for hospitalized asthmatic children using a clinical pathway

, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A clinical pathway for hospitalised children with asthma was examined. The pathway provided a protocol for admission, treatment and the discharge of asthmatic children, on the basis of a paediatric asthma score (PAS) and care provided by nursing and respiratory therapy staff. The staff were trained in four educational sessions. Type of intervention Patient (...) ), USA. Bibliographic details Kelly C S, Andersen C L, Pestian J P, Wenger A D, Finch A B, Strope G L, Luckstead E F. Improved outcomes for hospitalized asthmatic children using a clinical pathway. Annals of Allergy, Asthma and Immunology 2000; 84(5): 509-516 Other publications of related interest Comment: Annals of Allergy, Asthma and Immunology 2000;84:473-4. Indexing Status Subject indexing assigned by NLM MeSH Asthma /therapy; Child; Child, Preschool; Costs and Cost Analysis; Hospitalization

2000 NHS Economic Evaluation Database.

1009. A guideline implementation system using handheld computers for office management of asthma: effects on adherence and patient outcomes

to settings with different epidemiologic characteristics or treatment patterns. The study referred to children with asthma who presented with exacerbations and this was reflected in the authors' conclusions. Implications of the study The study results suggested that more research should be conducted before implementing guidelines for the management of asthmatic children. Physicians tended to resist some explicit recommendations, in particular the administration of oxygen therapy. Therefore, caution (...) A guideline implementation system using handheld computers for office management of asthma: effects on adherence and patient outcomes A guideline implementation system using handheld computers for office management of asthma: effects on adherence and patient outcomes A guideline implementation system using handheld computers for office management of asthma: effects on adherence and patient outcomes Shiffman R N, Freudigman K A, Brandt C A, Liaw Y, Navedo D D Record Status This is a critical

2000 NHS Economic Evaluation Database.

1010. Costs and effectiveness of spacer versus nebuliser in young children with moderate and severe acute asthma

Leversha A M, Campanella S G, Aickin R P, Asher M I. Costs and effectiveness of spacer versus nebuliser in young children with moderate and severe acute asthma. Journal of Pediatrics 2000; 136(4): 497-502 PubMedID Other publications of related interest Comment in: Journal of Pediatrics 2000;136(4):428-31. Indexing Status Subject indexing assigned by NLM MeSH Acute Disease; Albuterol /administration & Anti-Asthmatic Agents /administration & Asthma /drug therapy /economics; Child, Preschool; Cost-Benefit (...) Costs and effectiveness of spacer versus nebuliser in young children with moderate and severe acute asthma Costs and effectiveness of spacer versus nebuliser in young children with moderate and severe acute asthma Costs and effectiveness of spacer versus nebuliser in young children with moderate and severe acute asthma Leversha A M, Campanella S G, Aickin R P, Asher M I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each

2000 NHS Economic Evaluation Database.

1011. Cost effectiveness of inhaled fluticasone propionate vs inhaled triamcinolone acetonide in the treatment of persistent asthma

-Asthmatic Agents /economics /therapeutic use; Asthma /drug therapy /economics; Cost-Benefit Analysis; Treatment Outcome; Triamcinolone Acetonide /therapeutic use /economics AccessionNumber 22000001795 Date bibliographic record published 31/10/2002 Date abstract record published 31/10/2002 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York Homepage Options Print PubMed record Original research Share Message for NHS EED (...) Cost effectiveness of inhaled fluticasone propionate vs inhaled triamcinolone acetonide in the treatment of persistent asthma Cost effectiveness of inhaled fluticasone propionate vs inhaled triamcinolone acetonide in the treatment of persistent asthma Cost effectiveness of inhaled fluticasone propionate vs inhaled triamcinolone acetonide in the treatment of persistent asthma Stanford R H, Edwards L D, Rickard K A Record Status This is a critical abstract of an economic evaluation that meets

2000 NHS Economic Evaluation Database.

1012. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily (...) and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback B, Jenkins C, Price M J, Thwaites R M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Salmeterol/fluticasone propionate combination

2000 NHS Economic Evaluation Database.

1013. What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD?

the inclusion and exclusion criteria - Varying doses of corticosteroids used in the treatment of admitted patients with acute asthma appear to result in similar outcomes when pulmonary function data are examined. - Higher doses of corticosteroids do not appear to have an obvious therapeutic advantage for severe asthma patients - The results may not be generalisable to COPD patients, mild asthmatics, or patients with ventilatory support. - We are unable to determine the effect of differing doses (...) What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? What is the optimal dose of intravenous corticosteroid for initial management of acute exacerbations of asthma and COPD? Hender K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality

2000 Health Technology Assessment (HTA) Database.

1014. Inhaled corticosteroids for asthma

Inhaled corticosteroids for asthma Inhaled corticosteroids for asthma Inhaled corticosteroids for asthma Weber J Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Weber J. Inhaled corticosteroids for asthma. University HealthSystem Consortium (UHC). Drug Monograph. 2000 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise (...) therapeutic interchange. Each monograph includes comprehensive information from the primary literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Administration, Inhalation; Adrenal Cortex Hormones; Asthma /drug therapy Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700; Fax: 630-954

2000 Health Technology Assessment (HTA) Database.

1015. The cost effectiveness of eformoterol via Turbohaler and salmeterol via pressurised metered dose inhaler and metered dose powder inhaler in mild to moderate asthma

a justification for the choice of the comparators. Salmeterol was selected because it represented the most widely prescribed long-acting inhaled bronchodilator for asthmatic patients. On the other hand, prior studies have shown eformoterol, which has a rapid onset of action (one minute), to be an effective treatment for mild to moderate asthma. You should decide whether they are valid comparators in your own setting. Validity of estimate of measure of effectiveness The analysis of effectiveness was based (...) , in mild to moderate asthmatics. Respiratory Medicine 1999;93:236-44. Indexing Status Subject indexing assigned by CRD MeSH Adrenergic beta-Agonists /economics /therapeutic use /administration & Adult; Albuterol /economics /therapeutic use; Asthma /drug therapy; Beclomethasone /economics /therapeutic use; Clinical Trials as Topic; Comparative Study; Cost-Benefit Analysis; Drug Costs; Emergency Service, Hospital; Ethanolamines /economics /therapeutic use; Female; Great Britain; Health Care Costs

2000 NHS Economic Evaluation Database.

1016. Improving asthma care through audit

' section. Cost results The total costs of treatment rose from 3,378 in the pre-intervention phase to 4,189 in the post-intervention phase. However, the cost of treating asthma events decreased from 985 to 92. Therefore, the total asthma costs were 82 lower at the second assessment (a 1.9% reduction). Synthesis of costs and benefits Not relevant as a cost-consequences analysis was carried out. Authors' conclusions The implementation of a programme to improve the care of young asthmatic patients (...) Improving asthma care through audit Improving asthma care through audit Improving asthma care through audit Ayriss M D, Bruins R H, Davidson M, Goel A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A programme

2000 NHS Economic Evaluation Database.

1017. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma

Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 10. 2000 Authors' objectives To provide guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. Authors' conclusions Guidance 1.1 For children under the age of 5

2000 Health Technology Assessment (HTA) Database.

1018. Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial

Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial Baxter-Jones AD, Helms PJ, Russell G, Grant A, Ross S, Cairns JA, Ritchie L, Taylor R, Reid DM, Osman LM, Robins S, Fletcher ME Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Baxter-Jones AD, Helms PJ, Russell G, Grant A, Ross S, Cairns JA, Ritchie L, Taylor R, Reid DM, Osman LM, Robins S, Fletcher ME. Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial. Health Technology Assessment 2000; 4(28): 1-89 Authors

2000 Health Technology Assessment (HTA) Database.

1019. Treating asthma and COPD - a systematic review

Treating asthma and COPD - a systematic review Treating asthma and COPD - a systematic review Treating asthma and COPD - a systematic review Broman G, Bahtsevani C, Berg T, Eliasson M, Agens I et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Broman G, Bahtsevani C, Berg T, Eliasson M, Agens I et al. Treating asthma and COPD (...) - a systematic review. Stockholm: Swedish Council on Technology Assessment in Health Care (SBU) 2000: 571 Authors' objectives The intent of this report is to assess the scientific evidence underlying current treatment methods for asthma and COPD (chronic obstructive pulmonary disease) in adults and children. The report addresses primary prevention, pharmacological and surgical treatment, patient education, psychological methods, rehabilitation, climate therapy, and alternative medicine. Background

2000 Health Technology Assessment (HTA) Database.

1020. Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial Full Text available with Trip Pro

Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

2000 NIHR HTA programme